Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial

IMPORTANCE: Aflibercept biosimilars can expand available treatment options in retinal diseases and have the potential to improve patient access to safe and effective therapy. OBJECTIVE: To establish equivalence in efficacy and similarity in safety, pharmacokinetics, and immunogenicity of SB15 and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Se Joon, Bradvica, Mario, Vajas, Attila, Sagong, Min, Ernest, Jan, Studnicka, Jan, Veith, Miroslav, Wylegala, Edward, Patel, Sunil, Yun, Cheolmin, Orski, Michal, Astakhov, Sergei, Tóth-Molnár, Edit, Csutak, Adrienne, Enyedi, Lajos, Kim, Taehyung, Oh, Inkyung, Jang, Hyerin, Sadda, SriniVas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251242/
https://www.ncbi.nlm.nih.gov/pubmed/37289448
http://dx.doi.org/10.1001/jamaophthalmol.2023.2260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251242/
https://www.ncbi.nlm.nih.gov/pubmed/37289448
http://dx.doi.org/10.1001/jamaophthalmol.2023.2260

Ejemplares similares